These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 3052055)

  • 1. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
    De La Mata J; Blanco FJ; Gómez-Reino JJ
    Ann Rheum Dis; 1995 Nov; 54(11):881-5. PubMed ID: 7492236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis. Practical use of medications.
    Furst DE
    Postgrad Med; 1990 Feb; 87(3):79-92. PubMed ID: 2406713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.
    Jackson CG; Williams HJ
    Drugs; 1998 Sep; 56(3):337-44. PubMed ID: 9777310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
    van Everdingen AA; Jacobs JW; Siewertsz Van Reesema DR; Bijlsma JW
    Ann Intern Med; 2002 Jan; 136(1):1-12. PubMed ID: 11777359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis: a pharmacologic overview.
    Pinals RS
    Am Fam Physician; 1988 Mar; 37(3):145-52. PubMed ID: 2894754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative toxicity of disease-modifying antirheumatic drugs.
    Fries JF; Williams CA; Ramey D; Bloch DA
    Arthritis Rheum; 1993 Mar; 36(3):297-306. PubMed ID: 8452574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1995 May; 7(3):167-73. PubMed ID: 7612407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis: current concepts and management, Part 2.
    Sterling LP
    Am Pharm; 1990 Sep; NS30(9):49-54. PubMed ID: 1977296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying antirheumatic drugs.
    Conaghan PG; Lehmann T; Brooks P
    Curr Opin Rheumatol; 1997 May; 9(3):183-90. PubMed ID: 9204252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying antirheumatic drugs. Potential effects in older patients.
    Gardner G; Furst DE
    Drugs Aging; 1995 Dec; 7(6):420-37. PubMed ID: 8601050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate use in rheumatoid arthritis. A Clinician's perspective.
    Alarcón GS
    Immunopharmacology; 2000 May; 47(2-3):259-71. PubMed ID: 10878293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches to the treatment of rheumatoid disease.
    St Clair EW; Polisson RP
    Med Clin North Am; 1986 Mar; 70(2):285-304. PubMed ID: 3512929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate in rheumatoid arthritis. An update.
    Bannwarth B; Labat L; Moride Y; Schaeverbeke T
    Drugs; 1994 Jan; 47(1):25-50. PubMed ID: 7510620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    McConkey B
    Curr Opin Rheumatol; 1991 Jun; 3(3):348-54. PubMed ID: 1679342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.